FDA
-
-
-
-
-
-
-
Galmed to acquire Colospan for $4.5 million in medical device deal
-
-
-
-
-
-
-
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
-
-
-
-
-
-
-
Galmed to present cancer research at HEP-DART 2025 conference
-
-
-
-
-
-
-
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
-
-
-
-
-
-
-
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
-
-
-
-
-
-
-
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
-
328,164 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

